Faculty Profiles - MIZUNO, Masashi

Papers - MIZUNO, Masashi

Division display 201 - 220 of about 343 ／ All the affair displays >>

Effects of cinacalcet on magnesium and potassium metabolism in peritoneal dialysis patients with residual renal function International journal

Shibata Kanako, Ito Yasuhiko, Mizuno Masashi, Suzuki Yasuhiro, Hiramatsu Hideki, Ito Isao, Toda Susumu, Maruyama Shoichi, Matsuo Seiichi

Nihon Toseki Igakkai Zasshi Vol. 44 ( 10 ) page： 1007 - 1013 2011

Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society for Dialysis Therapy

Cinacalcet, a calcimimetic agent, binds to the calcium-sensing receptor (CaSR) and effectively decreases parathyroid hormone (PTH) secretion. CaSR is expressed in organs such as the parathyroid, kidneys, and bone. In the kidneys, it is expressed in the thick ascending limb (TAL) and the distal tubule (DT). In the TAL, activation of CaSR inhibits magnesium and calcium resorption by direct or indirect mechanisms. It also inhibits recycling of potassium back into the lumen by potassium channels. Peritoneal dialysis (PD) is thought to preserve the residual renal function (RRF) longer than hemodialysis. RRF is thus an important prognostic factor for PD patients. We investigated the effects on electrolyte balance and safety of cinacalcet. Six PD patients with RRF received once-daily oral cinacalcet at 25mg for two months. We examined the changes in levels of serum iPTH, and serum and urinary excretion of phosphorus, calcium, magnesium, and potassium for two months. Median (interquatile range: IQR) serum iPTH levels decreased significantly from 427.2 (351.2~1,313.3) pg/mL to 234.4 (86.0~721.3) pg/mL. Serum phosphorus levels and urinary excretion of phosphorus also decreased significantly. In contrast, concentrations of serum calcium, magnesium, and potassium, and urinary excretion of calcium, magnesium, and potassium did not change significantly. Serum levels of magnesium and potassium were not significantly altered, and were within the normal ranges (before, median 2.2 (IQR: 1.9~2.3) mg/dL, after, median 2.0 (IQR: 1.8~2.5) mg/dL for Mg; and before, median 4.5 (IQR: 4.4~5.2) mEq/L to 4.6 (IQR: 4.2~4.8) mEq/L for K). Based on these findings regarding the potassium and magnesium balance, cinacalcet appears to be useful and safe for the treatment of secondary hyperparathyroidism in PD patients with RRF.

DOI： 10.4009/jsdt.44.1007

CiNii Research

A Case of Acute Renal Failure Caused by Cholesterol Embolization after Carotid Artery Stenting that was Improved by Peritoneal Dialysis International journal

Mizuno Masashi, Ito Yasuhiko, Hayasaki Takahiro, Suzuki Yasuhiro, Hiramatsu Hideki, Toda Susumu, Mizuno Tomohiro, Tatematsu Miho, Ozaki Takenori, Yasuda Yoshinari, Sato Waichi, Tsuboi Naotake, Ito Isao, Maruyama Shoichi, Imai Enyu, Matsuo Seiichi

Internal Medicine Vol. 50 ( 16 ) page： 1719 - 1723 2011

Language：English Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Internal Medicine

A 68-year-old man was admitted with acute renal failure caused by cholesterol embolization after undergoing carotid artery stenting. Hemodialysis therapy (HD) was immediately required because of uremia, using nafamostat mesilate as an anticoagulant for HD. However, blue toes and gangrene of the feet worsened. To prevent use of anticoagulants and stabilize BP, HD was changed to peritoneal dialysis (PD). After starting PD, blue toes and gangrene improved markedly. Residual renal function also partially recovered. Although BP was unstable during HD, stability of BP and avoidance of anticoagulants during PD therapy might have contributed to the good results.<br>

DOI： 10.2169/internalmedicine.50.5358

Asymptomatic diverticulosis identified by computed tomography is not a risk factor for enteric peritonitis. Reviewed International journal

Toda S, Ito Y, Mizuno M, Suzuki Y, Ito I, Hiramatsu H, Ozaki T, Tsuboi N, Sato W, Maruyama S, Imai E, Matsuo S

Nephrol Dial Transplant Vol. ?? page： ?????? in press 2011

残腎機能を有する腹膜透析患者に対するシナカルセト投与時のMg、K代謝に及ぼす影響 Reviewed

柴田佳菜子, 伊藤恭彦, 水野正司, 鈴木康弘, 平松英樹, 伊藤功, 戸田晋, 丸山彰一, 中尾誠, 松尾清一

日本透析医学会会誌 Vol. 44 page： 1007-1013 2011

Pathological changes in chronic eosinophilic peritonitis in peritoneal dialysis patient. Reviewed International journal

Yuzawa Y, Ito Y, Mizuno M, Sawai A, Matsuo S

NDT plus Vol. 3 ( 4 ) page： 372 - 5 2010.8

Membrane complement regulators may protect against encapsular peritoneal sclerosis (EN) in a chronic proliferative peritoneal inflammation model of zymosan peritonitis in the rat International coauthorship International journal

Masashi Mizuno, Yasuhiko Ito, Tomohiro Mizuno, Yasuhiro Suzuki, Yukihiro Noda, Kiyofumi Yamada, Claire L. Harris, Noriko Okada, B. Paul Morgan, Seiichi Matsuo

MOLECULAR IMMUNOLOGY Vol. 47 ( 13 ) page： 2270 - 2270 2010.8

[Recent knowledge of complement system and the protective roles]. Invited

Mizuno M, Matsuo S

Nihon rinsho. Japanese journal of clinical medicine Vol. 68 Suppl 6 page： 49 - 52 2010.6

Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate Reviewed International coauthorship International journal

Mizutani Makoto, Ito Yasuhiko, Mizuno Masashi, Nishimura Hayato, Suzuki Yasuhiro, Hattori Ryohei, Matsukawa Yoshihisa, Imai Masaki, Oliver Noelynn, Goldschmeding Roel, Aten Jan, Krediet Raymond T., Yuzawa Yukio, Matsuo Seiichi

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY Vol. 298 ( 3 ) page： F721 - F733 2010.3

Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Reviewed

Mizutani M, Ito Y, Mizuno M, Nishimura H, Suzuki Y, Hattori R, Matsukawa Y, Imai M, Oliver N, Goldschmeding R, Aten J, Krediet RT, Yuzawa Y, Matsuo S.

Am J Physiol Renal Physiol Vol. 298 ( F721-F733 ) 2010

Recent knowledge of complement system and the protective roles. Invited

Mizuno M, Matsuo S.

Nippon Rinsho Vol. 68 page： 49-52 2010

Acute kidney injury presenting a feature of leukemic infiltration during therapy for chronic myelogenous leukemia. Reviewed

Yuzawa Y, Sato W, Masuda T, Hamada Y, Tatematsu M, Yasuda Y, Ozaki T, Ito I, Mizuno M, Maruyama S, Ito Y, Matsuo S.

Intern Med Vol. 49 page： 1139-1142 2010

名大腎不全システム研究会レジストリによる東海地区13施設の３年間（2005～2007）解析から得た、現在の腹膜透析療法の傾向と問題点

2. 水野正司、伊藤恭彦、田中章郎、平松英樹、渡辺緑子、稲熊大城、戸田晋、檀原敦、玉井宏史、倉田久嗣、春日弘毅、志水英明、松岡哲平、鶴田吉和、堀江正宣、成瀬友彦、平松武幸、伊藤功、丸山彰一、湯澤由紀夫、松尾清一

腎と透析 2010 （腎と透析別冊） Vol. 69 page： 638-640 2010

基礎カンファレンス　腹膜線維化に関する基礎研究の進歩, 腹膜線維症・機能不全と成長因子　特にTGF-β/CTGF/VEGFからの検討

3. 伊藤恭彦、水野正司、水谷真、西村勇人、鈴木康弘、澤井晶穂、鬼無洋、湯澤由紀夫、松尾清一

腎と透析 2010（腎と透析　別冊） Vol. 69 page： 128-131 2010

IX.免疫学的検査C.補体および関連物質 Invited Reviewed

水野正司, 松尾清一

日本臨床 Vol. Vol.68 page： 49 - 52 2010

基礎カンファレンス腹膜線維化に関する基礎研究の進歩、腹膜線維症・機能不全と成長因子

伊藤恭彦, 水野正司, 松尾清一

腎と透析2010 Vol. Vol.69 page： 128 - 131 2010

名大腎不全システム研究会レジストリによる東海地区13施設の3年間(2005～2007)解析から得た、現在の腹膜透析療法の傾向と問題点 Reviewed

水野正司, 伊藤恭彦, 松尾清一

腎と透析2010 Vol. Vol.69 page： 638 - 640 2010

Acute Kidney Injury Presenting a Feature of Leukemic Infiltration during Therapy for Chronic Myelogenous Leukemia International journal

Yukio Yuzawa, Waichi Sato, Tomohiro Masuda, Yuzuru Hamada, Miho Tatematsu, Yoshinari Yasuda, Takenori Ozaki, Isao Ito, Masashi Mizuno, Shoichi Maruyama, Yasuhiko Ito, Seiichi Matsuo

INTERNAL MEDICINE Vol. 49 ( 12 ) page： 1139 - 1142 2010

Language：English Publishing type：Research paper (scientific journal) Publisher：JAPAN SOC INTERNAL MEDICINE

Chronic myelogenous leukemia (CML) is a myeloproliferative disease that originates in abnormal pluripotent bone marrow stem cells and it is consistently associated with the Philadelphia chromosome and/or BCR/ABL fusion gene. Renal infiltration of leukemic cells is relatively rare in CML and is associated with renal impairment. We describe a patient who developed acute renal failure by tubulointerstitial nephropathy during treatment with imatinib mesylate for CML. The acute kidney injury was subsequently found to be due to direct leukemic infiltration. Treatment with hydroxycarbamide and prednisolone resulted in stabilization of the renal function for approximately 4 months. Leukemic infiltration into the kidney should always be considered when a patient with CML presents with renal impairment, regardless of the clinical stage, as the renal failure often responds well to chemotherapy.

DOI： 10.2169/internalmedicine.48.2747

名大腎不全システム研究会レジストリによる東海地区13施設の３年間（2005～2007）解析から得た、現在の腹膜透析療法の傾向と問題点

水野正司, 伊藤恭彦, 田中章郎, 平松英樹, 渡辺緑子, 稲熊大城, 戸田晋, 檀原敦, 玉井宏史, 倉田久嗣, 春日弘毅, 志水英明, 松岡哲平, 鶴田吉和, 堀江正宣, 成瀬友彦, 平松武幸, 伊藤功, 丸山彰一, 湯澤由紀夫, 松尾清一

腎と透析 2010 （腎と透析別冊） Vol. 69 page： 638-640 2010

基礎カンファレンス腹膜線維化に関する基礎研究の進歩, 腹膜線維症・機能不全と成長因子特にTGF-β/CTGF/VEGFからの検討

伊藤恭彦, 水野正司, 水谷真, 西村勇人, 鈴木康弘, 澤井晶穂, 鬼無洋, 湯澤由紀夫, 松尾清一

腎と透析 2010（腎と透析別冊） Vol. 69 page： 128-131 2010

Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice Reviewed International journal

Kei Kurata, Shoichi Maruyama, Sawako Kato, Waichi Sato, Jun-ichiro Yamamoto, Takenori Ozaki, Atsumi Nitta, Toshitaka Nabeshima, Yoshiki Morita, Masashi Mizuno, Yasuhiko Ito, Yukio Yuzawa, Seiichi Matsuo

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY Vol. 297 ( 6 ) page： F1510 - 7 2009.12

Language：English Publishing type：Research paper (scientific journal) Publisher：AMER PHYSIOLOGICAL SOC

Kurata K, Maruyama S, Kato S, Sato W, Yamamoto J, Ozaki T, Nitta A, Nabeshima T, Morita Y, Mizuno M, Ito Y, Yuzawa Y, Matsuo S. Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice. Am J Physiol Renal Physiol 297: F1510-F1517, 2009. doi:10.1152/ajprenal.90330.2008.-Peritoneal fibrosis (PF) is an important complication of peritoneal dialysis therapy. The present study was performed to examine the mechanisms of PF in view of the plasminogen activator (PA)/plasmin/matrix metalloproteinase (MMP) cascade. PF was induced in tissue-type PA (tPA) deficient mice and wild-type mice by intraperitoneal injection of chlorhexidine gluconate. Mice were killed on day 21, and tissue samples were taken. Histopathological studies were performed. Plasmin activity, gelatinases activity, and the levels of tPA, transforming growth factor-beta 1 (TGF-(sic)1), and MMP-2 mRNA were determined. Protein levels of MMP- 3, tissue inhibitor of metalloproteinases (TIMP)-1, -2, and -3, phospho-Smad3, membrane-type 1 (MT1)-MMP, and MT3-MMP were also studied. On day 21, tPA +/+ mice showed severe PF, whereas tPA -/- mice showed milder change. Submesothelial basement membranes were dissolved in tPA +/+ mice while they were relatively preserved in tPA -/- mice. The levels of macrophage infiltration, staining for alpha-smooth muscle actin (alpha-SMA) and collagen type III, and vascular density were all significantly lower in tPA -/- mice than in tPA +/+ mice. The levels of plasmin activity, pro- and active MMP- 2, mRNA expression of tPA and TGF-beta 1, and phospho-Smad3 protein were also lower in tPA -/- mice. No difference was observed between the two groups concerning the protein levels of MMP-3, TIMP-1, TIMP-2, TIMP-3, MT1-MMP, or MT3-MMP. These results indicate that the presence of tPA enhances inflammation, angiogenesis, and fibrogenesis in the peritoneum of the PF model mice. Activation of the PA/plasmin/MMP cascade may play a pivotal role in the pathogenesis of PF.

DOI： 10.1152/ajprenal.90330.2008

Web of Science

PubMed

researchmap

　 PREV - NEXT 　

<MIZUNO, Masashi>

Papers - MIZUNO, Masashi